Oncothyreon Looks To Leave Merck KGaA's Shadow With Two Cancer Candidates
This article was originally published in The Pink Sheet Daily
Executive Summary
While awaiting Phase III data on its partnered cancer vaccine Stimuvax, the Seattle biotech is advancing its own PI3 kinase inhibitor and follow-on vaccine projects.
You may also be interested in...
Oncothyreon Has Big Plans For Alpine Acquisition
One Seattle biotech took over another Seattle biotech in hopes of making a stronger oncology player that has the capabilities to develop its own drugs. It also hopes the acquisition will give it more business development opportunities.
Merck Serono Is Hoping It Pays To Plan Ahead With New Phase III Trial For Tecemotide
Merck Serono will conduct a second Phase III study of lung cancer vaccine tecemotide in patients treated concurrently with chemotherapy and radiation. The START trial, which also dosed patients receiving sequential therapy, failed but the predefined, concurrently treated subgroup showed greater median overall survival compared to placebo.
Merck Serono Is Hoping It Pays To Plan Ahead With New Phase III Trial For Tecemotide
Merck Serono will conduct a second Phase III study of lung cancer vaccine tecemotide in patients treated concurrently with chemotherapy and radiation. The START trial, which also dosed patients receiving sequential therapy, failed but the predefined, concurrently treated subgroup showed greater median overall survival compared to placebo.